Related Experiment Videos
Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis
G M Liuzzi1, M Trojano, M Fanelli
1Department of Biochemistry and Molecular Biology, University of Bari, Italy. m.g.liuzzi@biologia.uniba.it
Abstract:
Matrix metalloproteinase-9 (MMP-9) was detected by zymography and enzyme-linked immunosorbent assay (ELISA) in matched serum and cerebrospinal fluid (CSF) samples from patients with neurological diseases. Patients with relapsing-remitting multiple sclerosis (RR-MS) had serum and CSF MMP-9 levels comparable to those from patients with inflammatory neurological diseases (INDs), but higher than patients with non-inflammatory neurological diseases (NINDs) and healthy donors (HDs). MMP-9 increased in active RR-MS in comparison with inactive RR-MS implying that MMP-9 in MS is related with clinical disease activity. A correlation between the CSF/serum albumin (Q(AIb)) and CSF/serum MMP-9 (Q(MMP-9)) was observed in IND and NIND but not in RR-MS patients, indicating that CSF MMP-9 levels in NIND and IND patents could be influenced by serum MMP-9 and blood-brain barrier (BBB) permeability properties. MS patients had higher values of Q(MMP-9):Q(Alb)(MMP-9 index) than IND and NIND patients suggesting that in MS the increase in CSF MMP-9 could be due to intrathecal synthesis of MMP-9. A significant inverse correlation was found between MMP-9 and its endogenous inhibitor TIMP-1 in RR-MS indicating that in MS patients both the increase in MMP-9 and the decrease in TIMP-1 serum levels could contribute to BBB disruption and T-lymphocyte entry into the CNS.
Insights
Matrix metalloproteinase-9 (MMP-9) levels are elevated in patients with relapsing-remitting multiple sclerosis (RR-MS), particularly during active disease stages. This suggests MMP-9 may play a role in disease activity and central nervous system inflammation in MS.
Area of Science:
- Neuroimmunology
- Biochemistry
- Neurology
Background:
- Matrix metalloproteinase-9 (MMP-9) is implicated in neurological disorders.
- Understanding MMP-9's role in multiple sclerosis (MS) and other neurological diseases is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate and compare MMP-9 levels in serum and cerebrospinal fluid (CSF) across different neurological conditions, including relapsing-remitting multiple sclerosis (RR-MS).
- To explore the relationship between MMP-9 levels, disease activity, blood-brain barrier (BBB) integrity, and its endogenous inhibitor, TIMP-1, in MS patients.
Main Methods:
- Zymography and enzyme-linked immunosorbent assay (ELISA) were employed to quantify MMP-9 levels in matched serum and CSF samples.
- Albumin levels were measured to assess blood-brain barrier permeability (Q(AIb)).
- Correlations between MMP-9, albumin, and TIMP-1 were analyzed.
Main Results:
- Serum and CSF MMP-9 levels were higher in RR-MS patients compared to non-inflammatory neurological diseases (NINDs) and healthy donors (HDs), and increased with active RR-MS.
- While serum MMP-9 influenced CSF MMP-9 in IND and NIND patients (correlated with Q(AIb)), MS patients showed a distinct pattern (higher MMP-9 index), suggesting intrathecal synthesis.
- A significant inverse correlation between MMP-9 and TIMP-1 was observed in RR-MS, indicating a potential imbalance contributing to BBB disruption.
Conclusions:
- Elevated MMP-9 levels, particularly during active disease and potentially due to intrathecal synthesis, are associated with RR-MS.
- The interplay between increased MMP-9 and decreased TIMP-1 in MS may facilitate BBB breakdown and central nervous system inflammation.
- MMP-9 serves as a potential biomarker for disease activity and BBB disruption in MS.